FDA Clearance Tracker · K151378
Lumipulse G HE4 Immunoreaction Cartridges, Lumipulse G HE4 Calibrators
Last checked: Nov 20, 2026Latest source record: Nov 24, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Nov 24, 2015
Substantially Equivalent
Time to decision
186 days
Received May 22, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K151378
- Device name
- Lumipulse G HE4 Immunoreaction Cartridges, Lumipulse G HE4 Calibrators
- Applicant
- Fujirebio Diagnostics,Inc.
- Applicant location
- Malvern, PA
- Received
- May 22, 2015
- Decided
- Nov 24, 2015
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.6010
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OIU. The earliest in FDA's data is K072939, decided Jun 9, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K151378
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Fujirebio Diagnostics,Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250925 · Decided Dec 16, 2025 · 264 days after receipt
Device type: Cytokeratin Fragments 21-1 Eia Kit (OVK) · Laboratory Medicine & Pathology
- Lumipulse G pTau217/ß-Amyloid 1-42 Plasma RatioBreakthrough510(k)
K242706 · Decided May 16, 2025 · 249 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
- Lumipulse G ß-Amyloid Ratio (1-42/1-40)New device typeBreakthroughDe Novo
DEN200072 · Decided May 4, 2022 · 530 days after receipt
Device type: AlzheimerS Disease Pathology Assessment Test (QSE) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.